Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-30

Clinical Trial Update: Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease [NA]

View source ↗

Summary

Romidepsin was evaluated in patients with steroid-refractory graft-versus-host disease; the trial was terminated and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Romidepsin (romidepsin)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Graft Versus Host Disease | NA | Status: TERMINATED | Results posted: 2017-03-30